- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
Soley Therapeutics Presents Promising Preclinical Data for Cancer Drug Candidate
STX-6398 shows selective anti-tumor activity and biomarker-linked efficacy in preclinical studies.
Apr. 17, 2026 at 11:26pm
Got story updates? Submit your updates here. ›
Cutting-edge imaging techniques offer a glimpse into the molecular mechanisms that could be targeted by novel cancer therapies like Soley Therapeutics' STX-6398.South San Francisco TodaySoley Therapeutics, a biotechnology company, presented preclinical data at the AACR 2026 conference demonstrating the selective anti-tumor activity and biomarker-linked efficacy of their first-in-class drug candidate STX-6398, a CKAP2 modulator. The data supports the potential of small-molecule CKAP2 modulation as a novel therapeutic approach in cancer.
Why it matters
The development of new cancer therapies that target novel mechanisms of action is crucial for improving treatment options and outcomes for patients. STX-6398's unique mechanism of modulating CKAP2 could provide a new avenue for tackling difficult-to-treat cancers.
The details
The preclinical data presented by Soley Therapeutics showed that STX-6398 exhibited selective anti-tumor activity and was linked to specific biomarkers. Additionally, the compound demonstrated in vivo efficacy, supporting the potential of small-molecule CKAP2 modulation as a novel therapeutic approach in cancer.
- The data was presented at the AACR 2026 conference on April 17, 2026.
The players
Soley Therapeutics
A biotechnology company advancing novel therapeutics informed by integrated cell biology.
STX-6398
A first-in-class CKAP2 modulator drug candidate being developed by Soley Therapeutics.
The takeaway
The promising preclinical data on STX-6398 highlights the potential of targeting CKAP2 as a novel approach to cancer treatment, and Soley Therapeutics' drug discovery platform has rapidly identified this first-in-class candidate with selective anti-tumor activity.
